| Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, ... British journal of cancer 104 (8), 1262-1269, 2011 | 109 | 2011 |
| Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers G Allegrini, T Di Desidero, MT Barletta, A Fioravanti, P Orlandi, B Canu, ... Angiogenesis 15, 275-286, 2012 | 84 | 2012 |
| Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity A Di Paolo, G Bocci, M Polillo, M Del Re, T Di Desidero, M Lastella, ... Current Drug Metabolism 12 (10), 932-943, 2011 | 76 | 2011 |
| Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer T Di Desidero, P Xu, S Man, G Bocci, RS Kerbel Oncotarget 6 (40), 42396, 2015 | 59 | 2015 |
| Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib C Jedeszko, M Paez-Ribes, T Di Desidero, S Man, CR Lee, P Xu, ... Science Translational Medicine 7 (282), 282ra50-282ra50, 2015 | 56 | 2015 |
| CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo A Antonelli, G Bocci, C La Motta, SM Ferrari, P Fallahi, I Ruffilli, ... The Journal of Clinical Endocrinology & Metabolism 97 (4), E528-E536, 2012 | 55 | 2012 |
| CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo A Antonelli, G Bocci, P Fallahi, C La Motta, SM Ferrari, C Mancusi, ... The Journal of Clinical Endocrinology & Metabolism 99 (4), E572-E581, 2014 | 54 | 2014 |
| Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 G Bocci, A Fioravanti, P Orlandi, T Di Desidero, G Natale, G Fanelli, ... Neoplasia 14 (9), 833-IN11, 2012 | 53 | 2012 |
| VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide P Orlandi, A Fontana, A Fioravanti, T Di Desidero, L Galli, L Derosa, ... British journal of cancer 109 (4), 957-964, 2013 | 52 | 2013 |
| Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new … S Lazzeri, G Ripandelli, MS Sartini, M Parravano, M Varano, M Nardi, ... Angiogenesis 18, 397-432, 2015 | 51 | 2015 |
| Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer A Fioravanti, B Canu, G Alì, P Orlandi, G Allegrini, T Di Desidero, ... European journal of pharmacology 619 (1-3), 8-14, 2009 | 50 | 2009 |
| First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study V Marchetti, M Giorgi, A Fioravanti, R Finotello, S Citi, B Canu, P Orlandi, ... Investigational New Drugs 30, 1725-1730, 2012 | 49 | 2012 |
| Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo SM Ferrari, G Bocci, T Di Desidero, G Elia, I Ruffilli, F Ragusa, P Orlandi, ... Oncology reports 39 (5), 2225-2234, 2018 | 48 | 2018 |
| Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth K Parra, P Valenzuela, N Lerma, A Gallegos, LC Reza, G Rodriguez, ... British journal of cancer 116 (3), 324-334, 2017 | 45 | 2017 |
| VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration S Lazzeri, M Figus, P Orlandi, A Fioravanti, T Di Desidero, E Agosta, ... Pharmacogenomics 14 (6), 623-630, 2013 | 44 | 2013 |
| Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo B Canu, A Fioravanti, P Orlandi, T Di Desidero, G Alì, G Fontanini, ... Neoplasia 13 (3), 217-IN3, 2011 | 44 | 2011 |
| Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down … T Di Desidero, A Fioravanti, P Orlandi, B Canu, R Giannini, N Borrelli, ... The Journal of Clinical Endocrinology & Metabolism 98 (9), E1465-E1473, 2013 | 42 | 2013 |
| Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration‐resistant prostate cancer patients L Derosa, L Galli, P Orlandi, A Fioravanti, T Di Desidero, A Fontana, ... Cancer 120 (24), 3923-3931, 2014 | 41 | 2014 |
| Lessons from the fourth metronomic and anti-angiogenic therapy meeting, 24–25 June 2014, Milan G Bouche, N André, S Banavali, F Berthold, A Berruti, G Bocci, G Brandi, ... Ecancermedicalscience 8, 2014 | 39 | 2014 |
| Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration E Agosta, S Lazzeri, P Orlandi, M Figus, A Fioravanti, T Di Desidero, ... Pharmacogenomics 13 (9), 1037-1053, 2012 | 39 | 2012 |
Guido BocciAssociate Professor (BIO/14), University of Pisa在 med.unipi.it 的电子邮件经过验证
